Evidence map›Paper›PMID 27336739›Full record

ArticlePloS one2016

Seroreactivity against Specific L5P Antigen from Mycobacterium avium subsp. paratuberculosis in Children at Risk for T1D.

Magdalena Niegowska, Novella Rapini, Frank Biet, Simona Piccinini, Sylvie Bay, Roberta Lidano, Maria Luisa Manca Bitti, Leonardo A Sechi

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Neglected Facts onInternational journal of molecular sciences · 2022
    Review
  4. Article
  5. Presence of Infection byMicroorganisms · 2020
    Article
  6. The diabetes pandemic and associated infections: suggestions for clinical microbiology.Reviews in medical microbiology : a journal of the Pathological Society of Great Britain and Ireland · 2019
    Article
  7. Article
  8. Article
  9. Pathogenesis, Molecular Genetics, and Genomics ofFrontiers in veterinary science · 2017
    Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Magdalena NiegowskaDepartment of Biomedical Sciences, University of Sassari, 07100, Sassari, Italy.
Novella RapiniPediatric Diabetology Unit, Policlinico di Tor Vergata, University of Rome Tor Vergata, 00133, Rome, Italy.
Frank BietUMR1282, Infectiologie et Santé Publique (ISP-311), INRA Centre Val de Loire, F-37380, Nouzilly, France.
Simona PiccininiPediatric Diabetology Unit, Policlinico di Tor Vergata, University of Rome Tor Vergata, 00133, Rome, Italy.
Sylvie BayInstitut Pasteur, Unité de Chimie des Biomolécules, Département de Biologie Structurale et Chimie, Paris, France.
Roberta LidanoPediatric Diabetology Unit, Policlinico di Tor Vergata, University of Rome Tor Vergata, 00133, Rome, Italy.
Maria Luisa Manca BittiPediatric Diabetology Unit, Policlinico di Tor Vergata, University of Rome Tor Vergata, 00133, Rome, Italy.
Leonardo A SechiDepartment of Biomedical Sciences, University of Sassari, 07100, Sassari, Italy.
University of Rome Tor Vergata · ITUniversity of Sassari · ITCentre Val de Loire · FRInstitut Pasteur · FRPoliclinico Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisAlthough numerous environmental agents have been investigated over the years as possible triggers of type 1 diabetes (T1D), its causes remain unclear. We have already demonstrated an increased prevalence of antibodies against peptides derived from Mycobacterium avuim subsp. paratuberculosis (MAP) homologous to human zinc transporter 8 protein (ZnT8) and proinsulin in Italian subjects at risk for or affected by T1D. In this study, we compared titers of the previously detected antibodies with seroreactivity to MAP lipopentapetide (L5P) that recently emerged as a strong immunogenic component able to specifically distinguish MAP from other mycobacteria.

methodsPlasma of 32 children and youth at risk for T1D including follow-up samples and 42 age-matched healthy controls (HC) recruited at the Tor Vergata University Hospital in Rome was analyzed by indirect ELISA for the presence of antibodies against MAP-derived epitopes MAP3865c133-141, MAP3865c125-133, MAP2404c70-85 and MAP1,4αgbp157-173 along with their ZnT8 and proinsulin homologs. The data were analyzed through two-tailed Mann-Whitney U test and relation between variables was determined by principal component analysis.

resultsResponses to L5P were not detectable in subjects whose initial seroreactivity to MAP peptides and their human homologs was lost in follow-up samples, whereas anti-L5P antibodies appeared constantly in individuals with a stable immunity against MAP antigens. The overall coincidence in positivity to L5P and the four MAP epitopes both in children at risk for T1D and HC exceeded 90%.

conclusionsMAP-derived homologs may cross-react with ZnT8 and proinsulin peptides inducing immune responses at a young age in subjects predisposed for T1D. Thus, L5P may have a diagnostic value to immediately indicate the presence of anti-MAP seroreactivity when evaluation of a more complex antibody status is not required. Almost complete coincidence in responses to both types of antigens lends support to the involvement of MAP in T1D.

Identifiers

PMID27336739
PMCPMC4919038
OpenAlexW2460711129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.